Core Scientific Inc vs Enovix Corporation — how do they compare? Core Scientific Inc trades at $15.61 (market cap $5.12B), while Enovix Corporation trades at $2.54 (market cap $561.79M). The key difference: Core Scientific Inc is far larger — about 9.1× Enovix Corporation's market cap, and Core Scientific Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Enovix Corporation for 11 Days on average.
| CORZ | ENVX | |
|---|---|---|
Market Cap | $5.12B | $561.79M |
Volume | 9,296,664 | 5,898,906 |
Sector | Technology | Industrials |
52-Week High | $29.16 | $13.19 |
52-Week Low | $13.57 | $2.50 |
Typical Hold Time | 20 Days | 11 Days |
Enterprise Value | $7.65B | $623.49M |
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.94, down 4.44% today amid bearish technical signals. The stock shows weak fundamentals with a -324.9% net income margin and negative earnings misses in recent quarters. However, analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.46 consensus price target. Recent executive appointments and AI data center expansion plans provide growth catalysts despite current profitability challenges.
The outlook balances strong analyst conviction against fundamental weakness. While the AI infrastructure pivot offers long-term potential, investors face significant execution risks and negative cash flow. The stock trades near support levels with technical indicators suggesting caution, requiring careful monitoring of revenue growth and margin improvement for sustained recovery.
ENVX trades at $2.55, down 5.56% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with negative moving averages and oscillators. Fundamentally, the company continues to burn cash with a net income margin of -473.89% in 2026, though revenue growth remains positive at 32% year-over-year. Recent CEO transition and strategic focus on defense battery manufacturing create uncertainty about execution.
The outlook remains challenging with significant cash burn and negative profitability, though analyst consensus is bullish with a $10.75 price target representing 321% upside. Key risks include execution challenges, high cash consumption, and competitive pressures in the battery sector. The company's $552 million cash position provides runway but requires successful commercialization to justify valuation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →